Figure 5.

(a) NSMD approach for in vivo delivery of luciferase-encoded plasmid. Optical imaging of luciferase expression was performed in a mouse treated with the in vivo NSMD platform in the presence of luciferase reporter plasmid-encapsulated SNPs (pGL3⊂SNPs; 200 ng/site) at designated time points. The in vivo NSMD study exhibited high expression of pGL3, and a maximum luciferase signal was achieved 48 h postadministration of pGL3⊂SNPs. (b) Continuous monitoring of the luciferase expression in in vivo NSMD-treated mice along with control studies (w/o Ad-SiNWS). The luciferase levels in the NSMD study were significantly higher than those of the control group and peaked at 48 h postadministration of pGL3⊂SNPs.